Phase II study shows new cancer drug combination significantly delays breast cancer progression

The first randomised trial to investigate the use of trastuzumab emtansine (T-DM1) – an antibody-guided drug – for the initial treatment of HER2- (human epidermal growth factor receptor-2) positive metastatic breast cancer has shown that it makes a significant difference to the time women live without their disease worsening.

Read the whole article on Physorg

More from Physorg